End-of-day quote
Shenzhen S.E.
03:30:00 16/05/2024 am IST
|
5-day change
|
1st Jan Change
|
15.83
CNY
|
+0.25%
|
|
+1.47%
|
+2.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,285
|
27,436
|
41,354
|
25,222
|
17,996
|
18,510
|
-
|
-
|
Enterprise Value (EV)
1 |
15,285
|
27,436
|
41,354
|
25,222
|
17,996
|
18,510
|
18,510
|
18,510
|
P/E ratio
|
27.6
x
|
33.6
x
|
43.3
x
|
25.6
x
|
17.1
x
|
15.1
x
|
11.7
x
|
11.1
x
|
Yield
|
-
|
1.04%
|
0.81%
|
1.38%
|
2.05%
|
2.23%
|
3%
|
2.59%
|
Capitalization / Revenue
|
-
|
3.48
x
|
4.62
x
|
2.39
x
|
1.57
x
|
1.45
x
|
1.25
x
|
1.19
x
|
EV / Revenue
|
-
|
3.48
x
|
4.62
x
|
2.39
x
|
1.57
x
|
1.45
x
|
1.25
x
|
1.19
x
|
EV / EBITDA
|
-
|
-
|
27.9
x
|
18.1
x
|
11.3
x
|
11.5
x
|
8.63
x
|
8.91
x
|
EV / FCF
|
-
|
-
|
-479
x
|
30.7
x
|
43.9
x
|
91.2
x
|
11.7
x
|
10.2
x
|
FCF Yield
|
-
|
-
|
-0.21%
|
3.26%
|
2.28%
|
1.1%
|
8.55%
|
9.76%
|
Price to Book
|
-
|
6.25
x
|
8.17
x
|
4.61
x
|
2.91
x
|
2.61
x
|
2.22
x
|
1.99
x
|
Nbr of stocks (in thousands)
|
11,78,523
|
11,78,523
|
11,78,523
|
11,70,955
|
11,69,324
|
11,69,324
|
-
|
-
|
Reference price
2 |
12.97
|
23.28
|
35.09
|
21.54
|
15.39
|
15.83
|
15.83
|
15.83
|
Announcement Date
|
11/03/20
|
11/03/21
|
09/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
7,880
|
8,943
|
10,545
|
11,474
|
12,789
|
14,777
|
15,611
|
EBITDA
1 |
-
|
-
|
1,482
|
1,393
|
1,591
|
1,611
|
2,146
|
2,077
|
EBIT
1 |
-
|
969.7
|
1,119
|
1,012
|
1,220
|
1,405
|
1,827
|
1,914
|
Operating Margin
|
-
|
12.31%
|
12.52%
|
9.59%
|
10.63%
|
10.99%
|
12.36%
|
12.26%
|
Earnings before Tax (EBT)
1 |
-
|
961.2
|
1,114
|
1,012
|
1,205
|
1,401
|
1,821
|
1,904
|
Net income
1 |
-
|
816.7
|
955.6
|
989.2
|
1,055
|
1,231
|
1,590
|
1,688
|
Net margin
|
-
|
10.37%
|
10.69%
|
9.38%
|
9.2%
|
9.62%
|
10.76%
|
10.81%
|
EPS
2 |
0.4696
|
0.6930
|
0.8108
|
0.8425
|
0.9025
|
1.046
|
1.350
|
1.432
|
Free Cash Flow
1 |
-
|
-
|
-86.3
|
821.9
|
409.9
|
203
|
1,582
|
1,807
|
FCF margin
|
-
|
-
|
-0.97%
|
7.79%
|
3.57%
|
1.59%
|
10.71%
|
11.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
58.98%
|
25.76%
|
12.6%
|
73.72%
|
87.01%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
83.09%
|
38.84%
|
16.49%
|
99.51%
|
107.03%
|
Dividend per Share
2 |
-
|
0.2430
|
0.2850
|
0.2970
|
0.3160
|
0.3533
|
0.4750
|
0.4100
|
Announcement Date
|
11/03/20
|
11/03/21
|
09/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-86.3
|
822
|
410
|
203
|
1,582
|
1,807
|
ROE (net income / shareholders' equity)
|
20.2%
|
20.2%
|
19%
|
18.2%
|
17.5%
|
19.2%
|
17.9%
|
ROA (Net income/ Total Assets)
|
-
|
11.5%
|
-
|
8.51%
|
9.55%
|
10.7%
|
10.7%
|
Assets
1 |
-
|
8,329
|
-
|
12,394
|
12,887
|
14,868
|
15,779
|
Book Value Per Share
2 |
3.730
|
4.290
|
4.680
|
5.280
|
6.060
|
7.140
|
7.950
|
Cash Flow per Share
2 |
0.9000
|
0.5200
|
1.130
|
0.8800
|
1.230
|
1.780
|
1.720
|
Capex
1 |
300
|
702
|
504
|
622
|
217
|
314
|
186
|
Capex / Sales
|
3.81%
|
7.85%
|
4.78%
|
5.42%
|
1.7%
|
2.12%
|
1.19%
|
Announcement Date
|
11/03/21
|
09/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
15.83
CNY Average target price
17.75
CNY Spread / Average Target +12.13% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.86% | 2.56B | | +32.36% | 694B | | +30.77% | 593B | | -1.60% | 371B | | +20.07% | 331B | | +6.04% | 290B | | +14.77% | 239B | | +9.13% | 209B | | -3.97% | 209B | | +9.27% | 169B |
Other Pharmaceuticals
|